Share
9,044 Posts.
lightbulb Created with Sketch. 2374
clock Created with Sketch. 24/03/25
23:07
Share
Originally posted by TheAnalyst007:
↑
Opthea’s leadership team is perhaps the most compelling indicator of future success for me. We have an unusually remarkable blend of top-tier ophthalmology expertise, proven drug-development acumen, and a track record of guiding blockbuster therapies to approval. These are individuals who were instrumental in launching and expanding landmark wet AMD treatments such as Lucentis and Eylea. Mike Campbell, for example, played a central role in helping Lucentis dominate the market whilst at Genentech and later contributed to the pre-launch preparations for Beovu at Novartis. Meanwhile, clinical experts like Dr. Julie Clark and regulatory leaders like Dr. Fang Li have successfully navigated pivotal trials and assembled approval packages for major ophthalmic products, ensuring new therapies met high efficacy and safety standards. Renowned retina specialist Dr. Arshad Khanani, who has overseen more than 120 clinical trials, joined as Chief Medical Advisor—another strong endorsement of sozinibercept’s potential. Such seasoned professionals don’t typically join a biotech unless they see an extraordinary chance to improve on past successes. Their expertise covers every phase of the drug lifecycle, from optimizing Phase 3 endpoints to securing approvals and building commercial strategies. They’ve repeatedly transformed innovative research into leading therapies, and now they’re poised to do the same with sozinibercept. Early clinical results have already impressed these experts enough to commit their reputations, and that collective conviction strongly suggests that Opthea can not only replicate, but likely surpass, the achievements they’ve helped shape in the past. All the existing data in the world doesn't matter much relative to the importance of having an experienced management with proven track records backing your drug. I don't think we could have a better management team, I am confident that we have the biggest breakthrough in ophthalmology since anti-VEGF drugs were first invented two decades ago, and I think those in the industry who have both the expertise and experience of bringing these first drugs to market know that this right here is the real deal. The future of wet AMD treatment. We are certainly in great hands who know what they are doing and what must be done to get this to market, but more importantly, we have the validation of some of the brightest and most brilliant in the field.
Expand
Yet the trial was a failure.
(20min delay)